{"name":"QED Therapeutics, a BridgeBio company","slug":"qed-therapeutics-a-bridgebio-company","ticker":"","exchange":"","domain":"qedabridgebiocompany.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNcWFfN2JWYVp0QkhOOFAxM3dmVDRGWllqcVlJMS13b09MSi1fbXJPNXBHdDNsTFQ4ZmZKb3dNTXNsUlRpeWNWdjVuQ21rTTJNenROdXRRdlBoN1B0dHNJLU5hSVpUdG5FQXcyX1ZNY0lBN3d0VXI5QVgwTU5jZkg0VW54M2ZGVDg4VThkV2VWTDU?oc=5","date":"2025-08-12","type":"pipeline","source":"Yahoo Finance","summary":"Skeletal Dysplasia Market Growth Analysis 2025-2030 Featuring BioMarin Pharma, BridgeBio Pharma, Ascendis Pharma, Ipsen, QED Therapeutics and Other Major Players - Yahoo Finance","headline":"Skeletal Dysplasia Market Growth Analysis 2025-2030 Featuring BioMarin Pharma, BridgeBio Pharma, Ascendis Pharma, Ipsen,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQMGN0VWwwSDFGeE5XMVVXSDluRHJHMHRVR1F2QmpTbGZzZWRwX0FvcDFDU0lzSEo0V1ludEZRZVQ0RU9vaHJuSTRFMEs0Uy1VNlJzOXRYSjkzUlktM1BCVTNHUk9NU29GbVRFVVJzek5NY01YWnRVYkFEckhES0pHcm9haFB3S3dqd0toMXVzT2VsNEJ3dy10RVdiTkUxUWdy?oc=5","date":"2024-02-07","type":"deal","source":"Fierce Pharma","summary":"Kyowa Kirin pays $100M to partner with BridgeBio on potential dwarfism drug - Fierce Pharma","headline":"Kyowa Kirin pays $100M to partner with BridgeBio on potential dwarfism drug","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-01-09","type":"pipeline","source":"PR Newswire","summary":"Achondroplasia Treatment Drug Market to Register Positive Growth by 2032, Assesses DelveInsight | Key Companies in the Market - Ascendis Pharma, QED Therapeutics (BridgeBio), Novartis, Sanofi, RIBOMIC","headline":"Achondroplasia Treatment Drug Market to Register Positive Growth by 2032, Assesses DelveInsight | Key Companies in the M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxPTlZ3QUZOQ0g5Ukk0cW1kOXhCTXlDQXZEay1TNnUxd3FwblFOa0JJcDlmVVdPZ2xPSW93WHpBZWVKSmZfbk81azVqN05nRUZlWl8tQWNNX3JqY3dDVEpGUDJFNHZYTGNMTGFibmhRWHhxSTJBcHQ3MDA3Zk81Z29zX0kycm44bEhkVnZkUGVrZldrdlE4RW9qb0NISFlLTnpkUXdIVDhLREZqbmlDVU4zbG4teXFnN1ZKbTZpZFVXU3JJUXVoUkxFR0hya2E5QTNSOGRuVkdibmtwQTRxUW9BanR0T0txbFlPelRJcVB6ejNkeDlXTVhzYXlsQlJGMjk2UUpuNTlJSDNfRE9WRXgxM050UjN5QVM1MFNTTkZhQThzSXRzV2ZybUI5MmRJbFMxN01xaDN0elNzXzMzd3hpU0VlOWlmNWVX?oc=5","date":"2021-03-31","type":"pipeline","source":"GlobeNewswire","summary":"BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn - GlobeNewswire","headline":"BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQd3RlWlhodFNmWWZrYWI5cF9VVTU0VHhCMXRfQVlzR2pObkNvYWltNU5BVnpsMkIxLXlwZmZQX1RQeE5TOEQ1Zkk3Ni1nWWcwM3ZBaXQ5RGVpSDhDZjQzWVlsMjFraEg3aXZPc2kwX1RuSnV0VjlNNFlKT20wdW5uYThLVWptUzloX3djQTVlTjR2X0NYek54ejZBWEVOZmRncmVDNHhzZU9uMzVhcmpRbU1XdTZOLW9nNFJ3TDJsSQ?oc=5","date":"2020-08-11","type":"pipeline","source":"Fierce Biotech","summary":"Perceptive debuts LianBio with cancer and heart disease programs from BridgeBio, MyoKardia - Fierce Biotech","headline":"Perceptive debuts LianBio with cancer and heart disease programs from BridgeBio, MyoKardia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxPYURYSS1RN3puV24xcGVYNnR3NmRtTFZvbkdRN21Va1UwVm93V1NQUl9mc0c2a0hjNzVtMmNiT0V1cXVkVHJuOEUyX2lCc19jYWZrQ0pZeGlDRF9TTGdrdjExaUVOeENhMjFiTHVuZDdpUllSMW04ZFlXV2k0Njk4OExPWlFhbnRGNDBTMzIyNVhkdDdLOXcyVDNVWlhWN2VEdUl6dXNLSUhzV0hRTVE3ZG42QkdIdkQtaWZ5SEFiUUpaa1FiNG9JbEZ4My1odmhTOV9JR2RfVzZpZURSVUtDaFVwM05sWnBqSG1nVjBiQk50Tjhy?oc=5","date":"2020-08-11","type":"pipeline","source":"Business Wire","summary":"Perceptive Advisors Launches LianBio with Multiple Strategic Alliances and Establishes Operating Platform - Business Wire","headline":"Perceptive Advisors Launches LianBio with Multiple Strategic Alliances and Establishes Operating Platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxOam5vOGlCdk1kNW5UcTJJWElUb2RXa2ZIUFJjWUFDRlpkdWE2MEhiUUY4cXpieERzamlzaGNTUGJKbGZOclZSN1lac09oUDZrQzRHckpDQllwVy16QXg4NGk4MmVxZnVPREdHaU5CTTZvaW5ISTNFOTF1d1NTZHFzOEU1eHpYcVlCbUZGU1E2OTlicVI0OUVMTEEwQXI2RDNHMzU4bTVHeXFxZ3lVNmNIVzkwUFZqRUZ6eWVXc3NqRFp0N09CSlJERlE0NkZLZDhsRnhJcmx0bkV3SUl4WGtscjJCdXFHaTgxRmhhdFIyd1RiMHNLTF9nSm5LVDFvMWpZckJ6eUJMaGpGeWZMU3JWcjNfRDZyWjl5eThmREZLNmxhcG5rQUcwZmg3RQ?oc=5","date":"2019-10-17","type":"trial","source":"PR Newswire","summary":"QED and Parent Company BridgeBio Announce Preclinical Data Supporting Tolerability and Activity of Low-dose Infigratinib in Treating Achondroplasia - PR Newswire","headline":"QED and Parent Company BridgeBio Announce Preclinical Data Supporting Tolerability and Activity of Low-dose Infigratinib","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AJBVV95cUxOQ1ZrZUF3TU42RXNkdVpiVndQRFRxQW42VERVc3g3MDhyNUpVUFNPaW9zYWp6cEVueFZXSzBtTXY1ZjdBRzRucGF2eGl3WGVRNWlBTUFZamhhbThmWDNIRDd1ekY4V2JQN1pfUXc4eUdkd252aXNTN1dzVzZNUnJFWGNSTGdpdXY4N3dialBMdlNaNDctRVhUQmwxRXc1ZTZ5TkxhZk1BdDBWUXJiaGpicXU0UHFyaVhFVExianFaSTNQTnBUZi14NlNUVnZQU1JXdkxXMnBzbXduSE5wZE8wZmdWWGhjZVg3ZEJuSkdWRkRrSzQ0ZE1Tc3hXNnFNZTA3UFdYY1J3SWl0eHpfUXRaRzhrYVplRklvNFB0dU0wUi05X01GcnN0ZWlWSFFZLW5wUERXYnpIMHBUNnpibFR6NG00TG5UeUJfV0d0amFEZnI?oc=5","date":"2018-01-30","type":"deal","source":"PR Newswire","summary":"BridgeBio Pharma Licenses Late-Stage Oncology Drug Infigratinib to Tackle FGFR-Driven Maladies; Establishes New Subsidiary QED Therapeutics with $65 Million in Initial Financing - PR Newswire","headline":"BridgeBio Pharma Licenses Late-Stage Oncology Drug Infigratinib to Tackle FGFR-Driven Maladies; Establishes New Subsidia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQT3VMenNZdTFVdlZ4emdiUDhpRldSZW1fZDVJdmlkRE1JSzVaM01RaEpINkxXV2RaaEZtZ3RPSS1ibDk3NkV6VlBlUDQxTk1VaDBwdXZFMWNueVQ5Tk8taGV1Z3dRdTY4WWgwQUlHeUNyTEF3ckRBNVZTd3E0U1VETzZNdGhUeW9iU2hDY1V2c2oxaVJnenVWSURlY3Z3YXp2aGhiWEJNUFVObkJsZGdjYXJZbnZ4ZENF?oc=5","date":"2018-01-30","type":"pipeline","source":"BioSpace","summary":"BridgeBio Launches QED Therapeutics With $65M and an Abandoned Novartis Cancer Program - BioSpace","headline":"BridgeBio Launches QED Therapeutics With $65M and an Abandoned Novartis Cancer Program","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}